Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Net Cash Flow: 2010-2024

Historic Net Cash Flow for Kura Oncology (KURA) over the last 14 years, with Dec 2024 value amounting to $187.1 million.

  • Kura Oncology's Net Cash Flow rose 210.43% to $13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.8 million, marking a year-over-year change of. This contributed to the annual value of $187.1 million for FY2024, which is 1392.07% up from last year.
  • Kura Oncology's Net Cash Flow amounted to $187.1 million in FY2024, which was up 1,392.07% from -$14.5 million recorded in FY2023.
  • Kura Oncology's Net Cash Flow's 5-year high stood at $299.6 million during FY2020, with a 5-year trough of -$234.8 million in FY2021.
  • Moreover, its 3-year median value for Net Cash Flow was -$14.5 million (2023), whereas its average is $44.6 million.
  • In the last 5 years, Kura Oncology's Net Cash Flow soared by 2,890.89% in 2020 and then slumped by 178.39% in 2021.
  • Yearly analysis of 5 years shows Kura Oncology's Net Cash Flow stood at $299.6 million in 2020, then slumped by 178.39% to -$234.8 million in 2021, then spiked by 83.45% to -$38.9 million in 2022, then soared by 62.74% to -$14.5 million in 2023, then soared by 1,392.07% to $187.1 million in 2024.